[ad_1]
In two weeks, the results of three possible vaccines to combat COVID-19 were revealed. The first was the Pfizer vaccine, followed by modern pharmaceuticals and now Coronavac.
According to information, this Chinese vaccine Coronavac It is safe”.
The vaccine was tested in 744 volunteers between the ages of 18 and 59
According to a study published Tuesday in the magazine The lancet, to which the DN refers, the Chinese vaccine (potential) against COVID-19, is "safe" and managed to induce an antibody response in 97% of the healthy volunteers who were evaluated.
In all, there were 744 volunteers between the ages of 18 and 59, which helped show that antibody responses can be induced within 28 days of the first immunization. The Coronavac vaccine should be given in two doses 14 days apart.
Research for vaccine production also helped identify the ideal dose to generate the highest immune responses in phases one and two of the trials. Still, according to the study, the side effects resulting from vaccination were mild and disappeared within 48 hours. Basically just slight pain in the area where the volunteers were vaccinated.
More people to try
However, there is much work ahead. Now you need to try other age groups. Fengcai Zhu, a researcher at the Jiangsu Provincial Center for Disease Control and Prevention in China, said ...
Our results show that Coronavac is able to induce a rapid antibody response in approximately four weeks of immunization by administering two doses of the vaccine 14 days apart.
We believe this makes the vaccine suitable for emergency use during the pandemic. However, more studies are needed to verify how long the antibody response remains after vaccination.
In the long term, when the risk of covid-19 is lower, the findings suggest that giving two doses a month apart, rather than leaving two weeks apart, may be more appropriate for inducing stronger and potentially more immune responses. . lasting
This Coronavac vaccine is one of 48 candidates for vaccines against the new coronavirus. It is currently in development and is based on a SARS-CoV-2 viral strain, originally isolated from a Chinese patient.
[ad_2]
